FAQ: New Medication DR10624 for Severe Hypertriglyceridemia
TL;DR
DR10624 offers a competitive edge by reducing triglycerides over 60% and liver fat by 63%, outperforming current limited treatment options for severe hypertriglyceridemia.
DR10624 works by simultaneously activating FGF21, glucagon and GLP-1 receptors to control fat and sugar processing, administered via weekly subcutaneous injections.
This medication could significantly improve quality of life by reducing long-term risks of pancreatitis, liver disease and cardiovascular complications for patients with severe hypertriglyceridemia.
DR10624 represents the first investigational medication to target three metabolic receptors at once, achieving dramatic triglyceride reductions in a groundbreaking Phase 2 clinical trial.
Found this article helpful?
Share it with your network and spread the knowledge!
DR10624 is a first-of-its-kind investigational medication designed to treat severe hypertriglyceridemia (triglyceride levels between 500-2,000 mg/dL), a condition that increases risk of cardiovascular disease, pancreatitis, and liver damage.
In the Phase 2 clinical trial, DR10624 reduced triglyceride levels by more than 60% in most patients and also reduced liver fat by 63%, addressing both high triglycerides and associated liver health issues.
DR10624 is the first medication to simultaneously activate three receptors (FGF21, glucagon, and GLP-1 receptors) that control how the body processes fats and sugars, whereas current treatments like fibrates, omega-3 fatty acids, and statins often provide insufficient triglyceride lowering and limited effects on liver fat.
This research is significant because severe hypertriglyceridemia is often difficult to manage with existing treatments, and DR10624 could become a game-changer by reducing long-term risks of pancreatitis, MASLD (metabolic dysfunction-associated steatotic liver disease), and cardiovascular disease.
DR10624 is currently in Phase 2 clinical trials, and the findings presented are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The research was led by Dr. Jianping Li from Peking University First Hospital in China and was presented at the American Heart Association's Scientific Sessions 2025 in New Orleans.
Severe hypertriglyceridemia increases the risk of cardiovascular disease, pancreatitis, and excess fat in the liver (MASLD), which can progress to more serious liver conditions like MASH (metabolic dysfunction-associated steatohepatitis).
The trial was described as a small, short-term Phase 2 clinical trial lasting 12 weeks, though the exact number of participants was not specified in the content provided.
Readers should understand that these are preliminary results from a small Phase 2 trial, and the medication is not yet approved for general use, requiring further research and regulatory approval before becoming available to patients.
Curated from NewMediaWire
